Ruxolitinib targets DCs: For better or worse?

Ayalew Tefferi

doi:10.1182/blood-2013-07-509612

Ruxolitinib targets DCs: For better or worse?

Ayalew Tefferi

Hematology

Research output: Contribution to journal › Short survey › peer-review

7 Scopus citations

Abstract

In this issue of Blood, Heine et al demonstrate the dose-dependent inhibitory effect of ruxolitinib on the generation of dendritic cells (DCs) from monocytes. The drug also inhibited DC activation, tissue migration, and induction of allogeneic or antigen-specific T-cell responses, including in vivo viral clearance.

Original language	English (US)
Pages (from-to)	1096-1097
Number of pages	2
Journal	Blood
Volume	122
Issue number	7
DOIs	https://doi.org/10.1182/blood-2013-07-509612
State	Published - Aug 15 2013

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2013-07-509612

Cite this

@article{8d7b5c8cbc1441f598873e8e36355b65,

title = "Ruxolitinib targets DCs: For better or worse?",

abstract = "In this issue of Blood, Heine et al demonstrate the dose-dependent inhibitory effect of ruxolitinib on the generation of dendritic cells (DCs) from monocytes. The drug also inhibited DC activation, tissue migration, and induction of allogeneic or antigen-specific T-cell responses, including in vivo viral clearance.",

author = "Ayalew Tefferi",

year = "2013",

month = aug,

day = "15",

doi = "10.1182/blood-2013-07-509612",

language = "English (US)",

volume = "122",

pages = "1096--1097",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "7",

}

TY - JOUR

T1 - Ruxolitinib targets DCs

T2 - For better or worse?

AU - Tefferi, Ayalew

PY - 2013/8/15

Y1 - 2013/8/15

N2 - In this issue of Blood, Heine et al demonstrate the dose-dependent inhibitory effect of ruxolitinib on the generation of dendritic cells (DCs) from monocytes. The drug also inhibited DC activation, tissue migration, and induction of allogeneic or antigen-specific T-cell responses, including in vivo viral clearance.

AB - In this issue of Blood, Heine et al demonstrate the dose-dependent inhibitory effect of ruxolitinib on the generation of dendritic cells (DCs) from monocytes. The drug also inhibited DC activation, tissue migration, and induction of allogeneic or antigen-specific T-cell responses, including in vivo viral clearance.

UR - http://www.scopus.com/inward/record.url?scp=84887149115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887149115&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-07-509612

DO - 10.1182/blood-2013-07-509612

M3 - Short survey

C2 - 23950171

AN - SCOPUS:84887149115

SN - 0006-4971

VL - 122

SP - 1096

EP - 1097

JO - Blood

JF - Blood

IS - 7

ER -

Ruxolitinib targets DCs: For better or worse?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this